ClinicalTrials.gg
TerminatedNCT05261711(SCD)Updated Oct 15, 2026Results posted

AB1 in Adult Patients With Sickle Cell Disease (SCD)

A Phase 1/2 interventional study of AB1 in Sickle Cell Disease, sponsored by Nirmish Shah. Terminated at 3 sites in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Nirmish Shah · Phase 1/2, Interventional, and Treatment

How we know

Why this study was terminated
Study is terminated prior to its planned completion as anticipated by the protocol due to enrollment completion. Data clean up and analysis is being performed.
Updated Oct 15, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 733 studies in Anemia, Sickle Cell with a site in United States — 134 open to participants now, 185 under way, 16 of them phase 3. Anemia, Sickle Cell · United States.

Enrollment
396th of 559
16 · median 31
Started
2022
with 40 others
Phase 1/2
60 of 733
13 open now
Registered
580th of 733
by date

Among the 733 studies in Anemia, Sickle Cell with a site in United States, this one is the 396th largest by enrollment of the 559 interventional ones that give a count, is one of 41 that started in 2022, is one of 60 in phase 1/2, and was the 580th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

134 of the 733 studies in Anemia, Sickle Cell with a site in United States are open now. Recruiting first, the newest first:

129 more — sign in →

All 134 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 733 studies in Anemia, Sickle Cell with a site in United States, or all of them as a file.
02

Study summary

This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10mg, 12mg, 16mg, and 32mg. In each dose escalation cohort, each dose will be taken orally, once daily, for 8 weeks.

Read the detailed description

This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 4 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 16mg, and 32mg.

  • Cohort 1 - Two (2) patients will be enrolled at the 2mg dose level for 8 weeks of treatment. After both patients have received at least 4 weeks of treatment, if there are no adverse events ≥Grade 2 that are related (possibly, probably, or definitely) to the study drug, then the study will proceed to the next dose level. Note that if ≥Grade 2 toxicity is seen at this dose level, the study drug regimen may be modified (eg, twice or thrice weekly versus daily dosing).
  • Cohort 2 - Two (2) patients will be enrolled at the 4mg dose level for 8 weeks of treatment. After both patients have received at least 4 weeks of treatment, if there are no adverse events ≥Grade 2 that are related to the study drug, then the study will proceed to the next dose level.
  • Cohort 3 - Three (3) patients will be enrolled at the 8mg dose level for 8 weeks of treatment. After all patients have received at least 4 weeks of treatment, if \<2 patients experience a related adverse event ≥Grade 2, then the study will proceed to the next dose level. (If ≥2 patients experience a related adverse event ≥Grade 2, the previous cohort will be expanded.)
  • Cohort 4 - Three (3) patients will be enrolled at the 10mg dose level for 8 weeks of treatment. After all patients have received at least 4 weeks of treatment, if \<2 patients experience a related adverse event ≥Grade 2, then the study will proceed to the next dose level. (If ≥2 patients experience a related adverse event ≥Grade 2, the previous cohort will be expanded.)
  • Cohort 5 - Three (3) patients will be enrolled at the 12mg dose level for 8 weeks of treatment. After all patients have received at least 4 weeks of treatment, if \<2 patients experience a related adverse event ≥Grade 2, then the study will proceed to the next dose level. (If ≥2 patients experience a related adverse event ≥Grade 2, the previous cohort will be expanded.)
  • Cohort 6 - Three (3) patients will be enrolled at the 16mg dose level for 8 weeks of treatment. After all patients have received at least 4 weeks of treatment, if \<2 patients experience a related adverse event ≥Grade 2, then the study will proceed to the next and final dose level. (If ≥2 patients experience a related adverse event ≥Grade 2, the previous cohort will be expanded.)
  • Cohort 7 - Three (3) patients will be enrolled at the 32mg dose level for 8 weeks of treatment.
  • An additional cohort may be explored at the 24mg dose level if deemed appropriate based on safety and activity parameters.

If there are any adverse events Grade ≥2 that are related (possibly, probably, or definitely) to study drug, at the 4mg cohort or in ≥2 patients in any subsequent cohort, the dose may be reduced to the previous cohort and an additional 3-6 patients (total of up to 9) may be enrolled into that cohort. Additionally, if Hbf levels increase >15% (expressed as a percentage of total Hb) in any cohort, the cohort can be expanded to an additional 3 to 6 patients as well as continue to the next cohort if safety parameters have been met. In the expansion cohort, patients will receive study drug treatment for an additional 4 weeks (total of 12 weeks)..

Approximately 6 to 39 patients may be enrolled for the entire study. Patients are eligible to enroll in a higher cohort of the study after a minimum of one-month washout from AB1 dosing, if their HbF levels return to baseline (\<15%) and the investigator deems the patient eligible.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written,
  2. Age 18 to 45 years of age, inclusive at screening
  3. Confirmed SS or S-b0-thalassemia SCD
  4. Sickle crisis rate of 2-10 within the past year with no crisis in the last 28 days
  5. HbF \<8.6% of total at screening
  6. Regular compliance with comprehensive care and previous therapy -

Exclusion criteria

Exclusion Criteria:

  1. Experienced severe sepsis or septic shock within the previous 12 weeks
  2. Febrile illness in the 1 week prior to baseline visit
  3. Acute complications due to SCD (i.e., hospitalization, acute pain, or acute chest syndrome) in the 28 days prior to screening visit
  4. Plans for hospitalization, surgery, or other major procedures during the duration of the study or between screening and baseline
  5. ≥2X the or albumin \<2.0 mg/dL or direct (conjugated) ≥ 1.5 mg/dl*
  6. Serum creatinine >2.9 mg/dL and calculated \<30 mL/min# *
  7. count >800 x 109/L OR \<150 x 109/L*
  8. \<1.5 x 109/L*
  9. Currently pregnant or breastfeeding
  10. Female of active $ who is unwilling or unable to adhere to the requirements specified in the protocol
  11. Male with female partner(s) of childbearing potential$ who is unwilling or unable to adhere to the contraception requirements specified in the protocol
  12. Altered mental status or recurrent seizures requiring anti-seizure medications
  13. Moribund or any concurrent disease (e.g., hepatic, renal, cardiac, metabolic) of such severity that death within 24 weeks is likely
  14. Concurrent diagnosis of including MDS, leukemia, or an abnormal karyotype
  15. Known Vitamin-B12, folate, or iron deficiency
  16. (NYHA) class III/IV status
  17. Eastern Co-operative Oncology Group () performance status ≥3
  18. Participant is on chronic transfusion therapy (e.g., for history of or stroke) and medically to discontinue transfusions (unless multiple allo-antibodies prevent the patient from getting transfusions as scheduled)
  19. Blood transfusion in the 28 days prior to screening visit or between screening and baseline visits
  20. Known history of illicit drug or alcohol abuse within the past 12 months.
  21. Current treatment with Oxbryta or Adakveo (must be off therapy for 30 days for Oxbryta with no plans to restart and off therapy for 3 months for Adakveo with no plans to restart)
  22. Other experimental or drug therapy in the past 28 days -
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    AB1

    AB1 is the investigational product in this study taken orally, once daily, for 8 weeks. This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg.

    Drug: AB1

Interventions

  • DrugAB1

    This will be an open-label, dose escalating study with a starting dose of 2mg. Up to 6 additional cohorts will be enrolled at subsequently higher doses of 4mg, 8mg, 10 mg, 12 mg, 16mg, and 32mg. Each dose will be taken orally, once daily, for 8 weeks

06

What researchers measure

Primary outcomes

  1. Total Number of Adverse Events/Serious Adverse Events as Measured by Patient Report/Medical Records

    Time frame: From the time of consent up to 12 months

  2. Number of Participants With ≥Grade 2 Study Related Adverse Events as Measured by Patient Report/Medical Record

    Adverse events that cause enough discomfort to interfere with usual daily activity; may warrant therapeutic intervention

    Time frame: From the time of consent up to 12 months

Secondary outcomes

  1. Change in Cmax as Measured by Blood Test

    Cmax is defined as the highest concentration a drug achieves in the bloodstream.

    Time frame: Baseline, week 4, week 8, week 10

  2. Change in Tmax as Measured by Blood Test

    Tmax is defined as the time required to reach Cmax.

    Time frame: Baseline, week 4, week 8, week 10

  3. Change in T1/2 (Half Life) as Measured by Blood Test

    T1/2 (half life) is defined as the time required for the plasma concentration of a drug to decrease by half during the elimination phase.

    Time frame: Baseline, week 4, week 8, week 10

  4. Change in AUC O-t as Measured by Blood Test

    AUC o-t (Area Under the Curve from time zero to the last measurable concentration) measures a drug's total exposure in the bloodstream over a specific duration.

    Time frame: Baseline, week 4, week 8, week 10

  5. Change in Dose Normalized AUC O-inf as Measured by Blood Test

    AUC o-inf (Area Under the Curve from time zero to infinity) is a vital metric that quantifies total drug exposure in the bloodstream. It represents the total amount of an administered drug that enters systemic circulation, from the moment it is given until it is completely eliminated from the body.

    Time frame: Baseline, week 4, week 8, week 10

  6. Change in Clearance (CL) as Measured by Blood Test

    Clearance (CL) is the fundamental parameter measuring how efficiently the body removes a drug from systemic circulation. It represents the volume of plasma completely cleared of a drug per unit of time.

    Time frame: Baseline, week 4, week 8, week 10

  7. Change in Volume of Distribution (Vz) as Measured by Blood Test

    Volume of distribution (Vz) represents the apparent volume of distribution during the terminal phase. It relates the amount of drug in the body to the plasma concentration specifically during the drug's elimination phase.

    Time frame: Baseline, week 4, week 8, week 10

  8. Change in Vss (Volume of Distribution at Steady State) as Measured by Blood Test

    Vss (Volume of Distribution at Steady State) is a core pharmacokinetic parameter that defines the theoretical volume a drug would occupy if it were uniformly distributed at its steady-state concentration. It represents the actual blood and tissue volume the drug penetrates without being skewed by the terminal elimination phase.

    Time frame: Baseline, week 4, week 8, week 10

  9. Change in Percentage of Total Percentage of Total Hemoglobin (HB) as Measured by HPLC (High-Performance Liquid Chromatography)

    Reported as the percent change from baseline to week 10.

    Time frame: Screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12

  10. Change in Percentage of F-cells Measured by Flow Cytometry

    Reported as the percent change from baseline to week 10.

    Time frame: Screening, baseline, week 2,week 4, week 6, week 8, week 10, week 12

  11. Change in Percent Reticulocytes as Measured by Blood Tests

    Time frame: Screening, baseline, week 2,week 4, week 6, week 8, week 10, week 12

07

Results

Posted Oct 15, 2026

Participant flow

Participant flow — Overall Study
MilestoneAB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)
Started2254
Completed2254
Not completed0000

Outcome measures

PrimaryTotal Number of Adverse Events/Serious Adverse Events as Measured by Patient Report/Medical Records
Time frame:
From the time of consent up to 12 months
Reported as:
Number · adverse events
Total Number of Adverse Events/Serious Adverse Events as Measured by Patient Report/Medical Records
adverse eventsAB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)
Total Number of Adverse Events/Serious Adverse Events as Measured by Patient Report/Medical Records621117
PrimaryNumber of Participants With ≥Grade 2 Study Related Adverse Events as Measured by Patient Report/Medical Record

Adverse events that cause enough discomfort to interfere with usual daily activity; may warrant therapeutic intervention

Time frame:
From the time of consent up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With ≥Grade 2 Study Related Adverse Events as Measured by Patient Report/Medical Record
ParticipantsAB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)
Number of Participants With ≥Grade 2 Study Related Adverse Events as Measured by Patient Report/Medical Record1123
SecondaryChange in Cmax as Measured by Blood Test

Cmax is defined as the highest concentration a drug achieves in the bloodstream.

Time frame:
Baseline, week 4, week 8, week 10

No measurements were reported for this outcome.

SecondaryChange in Tmax as Measured by Blood Test

Tmax is defined as the time required to reach Cmax.

Time frame:
Baseline, week 4, week 8, week 10

No measurements were reported for this outcome.

SecondaryChange in T1/2 (Half Life) as Measured by Blood Test

T1/2 (half life) is defined as the time required for the plasma concentration of a drug to decrease by half during the elimination phase.

Time frame:
Baseline, week 4, week 8, week 10

No measurements were reported for this outcome.

SecondaryChange in AUC O-t as Measured by Blood Test

AUC o-t (Area Under the Curve from time zero to the last measurable concentration) measures a drug's total exposure in the bloodstream over a specific duration.

Time frame:
Baseline, week 4, week 8, week 10

No measurements were reported for this outcome.

SecondaryChange in Dose Normalized AUC O-inf as Measured by Blood Test

AUC o-inf (Area Under the Curve from time zero to infinity) is a vital metric that quantifies total drug exposure in the bloodstream. It represents the total amount of an administered drug that enters systemic circulation, from the moment it is given until it is completely eliminated from the body.

Time frame:
Baseline, week 4, week 8, week 10

No measurements were reported for this outcome.

SecondaryChange in Clearance (CL) as Measured by Blood Test

Clearance (CL) is the fundamental parameter measuring how efficiently the body removes a drug from systemic circulation. It represents the volume of plasma completely cleared of a drug per unit of time.

Time frame:
Baseline, week 4, week 8, week 10

No measurements were reported for this outcome.

SecondaryChange in Volume of Distribution (Vz) as Measured by Blood Test

Volume of distribution (Vz) represents the apparent volume of distribution during the terminal phase. It relates the amount of drug in the body to the plasma concentration specifically during the drug's elimination phase.

Time frame:
Baseline, week 4, week 8, week 10

No measurements were reported for this outcome.

SecondaryChange in Vss (Volume of Distribution at Steady State) as Measured by Blood Test

Vss (Volume of Distribution at Steady State) is a core pharmacokinetic parameter that defines the theoretical volume a drug would occupy if it were uniformly distributed at its steady-state concentration. It represents the actual blood and tissue volume the drug penetrates without being skewed by the terminal elimination phase.

Time frame:
Baseline, week 4, week 8, week 10

No measurements were reported for this outcome.

SecondaryChange in Percentage of Total Percentage of Total Hemoglobin (HB) as Measured by HPLC (High-Performance Liquid Chromatography)

Reported as the percent change from baseline to week 10.

Time frame:
Screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12
Reported as:
Mean · percentage of change
Change in Percentage of Total Percentage of Total Hemoglobin (HB) as Measured by HPLC (High-Performance Liquid Chromatography)
percentage of changeAB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)
Change in Percentage of Total Percentage of Total Hemoglobin (HB) as Measured by HPLC (High-Performance Liquid Chromatography)2.05 ± 0.851.30 ± 0.802.30 ± 0—
SecondaryChange in Percentage of F-cells Measured by Flow Cytometry

Reported as the percent change from baseline to week 10.

Time frame:
Screening, baseline, week 2,week 4, week 6, week 8, week 10, week 12
Reported as:
Mean · percentage of change
Change in Percentage of F-cells Measured by Flow Cytometry
percentage of changeAB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)
Change in Percentage of F-cells Measured by Flow Cytometry1.60 ± 4.2019.05 ± 18.554.95 ± 8.45—
SecondaryChange in Percent Reticulocytes as Measured by Blood Tests
Time frame:
Screening, baseline, week 2,week 4, week 6, week 8, week 10, week 12

No measurements were reported for this outcome.

Adverse events

Collected over From the time of consent up to 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AB1 Treatment - 2 mg Dose (Cohort 1)0/2 (0%)1/2 (50%)2/2 (100%)
AB1 Treatment - 4 mg Dose (Cohort 2)0/2 (0%)1/2 (50%)1/2 (50%)
AB1 Treatment - 8 mg Dose (Cohort 3)0/5 (0%)2/5 (40%)5/5 (100%)
AB1 Treatment - 10 mg Dose (Cohort 4)0/4 (0%)3/4 (75%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventAB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)
PneumoniaRespiratory, thoracic and mediastinal disorders1/20/20/50/4
Vaso-Occlusive CrisisVascular disorders0/21/21/50/4
Acute Infectious DiarrheaGastrointestinal disorders0/20/20/51/4
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)Investigations0/20/20/51/4
Sickle Cell Pain CrisisBlood and lymphatic system disorders0/20/20/51/4
E. Coli ColitisGastrointestinal disorders0/20/21/50/4
Most frequent other events
Showing 10 of 21
Most frequent other events
EventAB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)
RashSkin and subcutaneous tissue disorders1/21/20/51/4
Mild NauseaGastrointestinal disorders1/20/20/50/4
Intermittent Headaches Pain 9/10General disorders1/20/20/50/4
Nausea with VomitingGastrointestinal disorders1/20/20/51/4
DiarrheaGastrointestinal disorders0/20/20/52/4
Intermittent FeverGeneral disorders0/20/20/51/4
DehydrationGeneral disorders0/20/20/51/4
Upper respiratory infection symptomsRespiratory, thoracic and mediastinal disorders0/20/20/51/4
FatigueGeneral disorders0/20/21/51/4
Stiff NeckMusculoskeletal and connective tissue disorders0/20/20/51/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)AB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)Total
Mean29.50 ± 1.5028.40 ± 4.0029.40 ± 3.4041.25 ± 8.2632.85 ± 7.73
Sex: Female, Male
Sex: Female, Male(Participants)AB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)Total
Female10236
Male12317
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)Total
Hispanic or Latino00000
Not Hispanic or Latino225413
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)Total
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American224412
White00101
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)AB1 Treatment - 2 mg Dose (Cohort 1)AB1 Treatment - 4 mg Dose (Cohort 2)AB1 Treatment - 8 mg Dose (Cohort 3)AB1 Treatment - 10 mg Dose (Cohort 4)Total
United States225413
08

Study locations

3 sites
  • Augusta University Medical Center
    Augusta, Georgia 30912, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • East Carolina University
    Greenville, North Carolina 27834, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Oct 2024, 21 months.

Results were first posted in Oct 2026, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2022
First posted
Mar 2, 2022
StartActual
Dec 5, 2022
Primary completionActual
Oct 1, 2024
CompletionActual
Oct 1, 2024
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 15, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedTotal Number of adverse eventsAdverse Events/serious adverse eventsSerious Adverse Events as measuredMeasured by patient reportPatient Report/medical recordsMedical RecordsTime frame: From the time of consent up to 12 months
  • EditedNumber of Participants With ≥Grade 2 study related adverse eventsStudy Related Adverse Events as measuredMeasured by patient reportPatient Report/medical recordMedical RecordTime frame: From the time of consent up to 12 months
Oct 15, 2026
Documents
Secondary outcomes
11 edited
What changed in the outcomes
  • EditedChange in Cmax as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
  • EditedChange in tmaxTmax as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
  • EditedChange in t1T1/2 (Half Life) as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
  • EditedChange in AUC oO-t as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
  • EditedChange in dose normalizedDose Normalized AUC oO-inf as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
  • EditedChange in Clearance (CL) as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
  • EditedChange in Volume of Distribution (Vz) as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
  • EditedChange in Vss (Volume of Distribution at Steady State) as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
  • EditedChange in percentagePercentage of total percentageTotal Percentage of total hemoglobinTotal Hemoglobin (HB) as measuredMeasured by HPLC (High-Performance Liquid Chromatography)Time frame: Screening, baseline, week2,week4, week6, week8, week10, week12 → Screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12
  • EditedChange in percentagePercentage of F-cells measuredMeasured by flow cytometryFlow CytometryTime frame: Screening, baseline, week2,week4, week6, week8, week10, week12 → Screening, baseline, week 2,week 4, week 6, week 8, week 10, week 12
  • EditedChange in percent reticulocytesPercent Reticulocytes as measuredMeasured by blood testsBlood TestsTime frame: Screening, baseline, week2,week4, week6, week8, week10, week12 → Screening, baseline, week 2,week 4, week 6, week 8, week 10, week 12
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedTotal Number of adverse eventsAdverse Events/serious adverse eventsSerious Adverse Events as measuredMeasured by patient reportPatient Report/medical recordsMedical RecordsTime frame: From the time of consent up to 12 months
    • EditedNumber of Participants With ≥Grade 2 study related adverse eventsStudy Related Adverse Events as measuredMeasured by patient reportPatient Report/medical recordMedical RecordTime frame: From the time of consent up to 12 months
    Secondary outcomes 11 edited
    What changed in the outcomes
    • EditedChange in Cmax as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
    • EditedChange in tmaxTmax as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
    • EditedChange in t1T1/2 (Half Life) as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
    • EditedChange in AUC oO-t as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
    • EditedChange in dose normalizedDose Normalized AUC oO-inf as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
    • EditedChange in Clearance (CL) as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
    • EditedChange in Volume of Distribution (Vz) as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
    • EditedChange in Vss (Volume of Distribution at Steady State) as measuredMeasured by blood testBlood TestTime frame: Baseline, week4, week8, week10 → Baseline, week 4, week 8, week 10
    • EditedChange in percentagePercentage of total percentageTotal Percentage of total hemoglobinTotal Hemoglobin (HB) as measuredMeasured by HPLC (High-Performance Liquid Chromatography)Time frame: Screening, baseline, week2,week4, week6, week8, week10, week12 → Screening, baseline, week 2, week 4, week 6, week 8, week 10, week 12
    • EditedChange in percentagePercentage of F-cells measuredMeasured by flow cytometryFlow CytometryTime frame: Screening, baseline, week2,week4, week6, week8, week10, week12 → Screening, baseline, week 2,week 4, week 6, week 8, week 10, week 12
    • EditedChange in percent reticulocytesPercent Reticulocytes as measuredMeasured by blood testsBlood TestsTime frame: Screening, baseline, week2,week4, week6, week8, week10, week12 → Screening, baseline, week 2,week 4, week 6, week 8, week 10, week 12
    + 5 other changes: index terms, identifiers, verification date, registry dates and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05261711
Lead sponsor
Nirmish Shah
Responsible party
Nirmish Shah (Associate Professor of Medicine, Duke University) — Sponsor-investigator
First posted
Mar 2, 2022
Start date
Dec 5, 2022
Primary completion
Oct 1, 2024
Completion
Oct 1, 2024
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Study contacts

Nirmish Shah, MD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion